9月25日 - ** Organogenesis ORGO.O股价在延时交易中下跌11.1%，至4.16美元
** 公司称其试验性疗法ReNu在治疗膝骨关节炎的第二次后期试验中未达到主要目标，尽管在减轻疼痛方面有数字上的改善
** 膝关节骨性关节炎是一种退行性关节疾病，膝关节内的保护性软骨会磨损，导致疼痛、僵硬、肿胀，活动时有磨擦或噼啪声。
** 截至上一交易日收盘，股价累计上涨 46.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.